Stéphanie Blanchard

719 total citations
29 papers, 548 citations indexed

About

Stéphanie Blanchard is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Stéphanie Blanchard has authored 29 papers receiving a total of 548 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 12 papers in Oncology and 7 papers in Organic Chemistry. Recurrent topics in Stéphanie Blanchard's work include Synthesis and Biological Evaluation (6 papers), Cancer-related Molecular Pathways (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Stéphanie Blanchard is often cited by papers focused on Synthesis and Biological Evaluation (6 papers), Cancer-related Molecular Pathways (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Stéphanie Blanchard collaborates with scholars based in Singapore, United States and France. Stéphanie Blanchard's co-authors include Anders Poulsen, Kee Chuan Goh, Brian Dymock, Meredith Williams, Anthony D. William, Harish Nagaraj, Kantharaj Ethirajulu, Eric T. Sun, Haishan Wang and Jeanette M. Wood and has published in prestigious journals such as The Journal of Chemical Physics, Journal of Clinical Oncology and Blood.

In The Last Decade

Stéphanie Blanchard

28 papers receiving 533 citations

Peers

Countries citing papers authored by Stéphanie Blanchard

Since Specialization

Citations

This map shows the geographic impact of Stéphanie Blanchard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stéphanie Blanchard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stéphanie Blanchard more than expected).

Fields of papers citing papers by Stéphanie Blanchard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stéphanie Blanchard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stéphanie Blanchard. The network helps show where Stéphanie Blanchard may publish in the future.

Co-authorship network of co-authors of Stéphanie Blanchard

This figure shows the co-authorship network connecting the top 25 collaborators of Stéphanie Blanchard. A scholar is included among the top collaborators of Stéphanie Blanchard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stéphanie Blanchard. Stéphanie Blanchard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Quantitation of the piezoelectric coefficients of room temperature ionic liquids 2025 ·The Journal of Chemical Physics ·Sunday J. Olusegun, Stéphanie Blanchard, Gary A. Baker, G. J. Blanchard	2
2	Clinical activity of EBC-129, a first-in class, anti N256-glycosylated CEACAM5 and CEACAM6 antibody-drug conjugate (ADC), in patients with pancreatic ductal adenocarcinoma (PDAC) in a phase 1 study. 2025 ·Journal of Clinical Oncology ·Robert W. Lentz, Matthew Chau Hsien Ng, Wei Peng Yong, (unknown), Inderjeet Singh, (unknown), (unknown), Stéphanie Blanchard, Ranjani Nellore, (unknown), (unknown), Chek Shik Lim, (unknown), (unknown), (unknown), (unknown), (unknown), Joe Yeong, (unknown)	1
3	653P A phase I dose escalation study of EBC-129, a first-in class, anti N-glycosylated CEACAM5 & CEACAM6 antibody-drug conjugate (ADC) in patients with solid tumors 2024 ·Annals of Oncology ·Matthew Chau Hsien Ng, Wei Peng Yong, (unknown), Robert W. Lentz, (unknown), (unknown), Stéphanie Blanchard, Ranjani Nellore, (unknown), (unknown), Joel Louis Lim, (unknown), (unknown), (unknown), (unknown), Vishal Pendharkar, Joe Yeong, (unknown)	0
4	First‐in‐Human, Healthy Volunteers Integrated Protocol of ETC‐206, an Oral Mnk 1/2 Kinase Inhibitor Oncology Drug 2019 ·Clinical and Translational Science ·Vincenzo Teneggi, Veronica Novotny‐Diermayr, (unknown), (unknown), Pauline Yeo, Kantharaj Ethirajulu, (unknown), Stéphanie Blanchard, Ranjani Nellore, (unknown), Roberto Goméni, (unknown), (unknown), (unknown), Yang Cao, Alex Matter	11
5	Phase I extension study of ETC-159 an oral PORCN inhibitor administered with bone protective treatment, in patients with advanced solid tumours 2018 ·Annals of Oncology ·David S.P. Tan, Matthew Chau Hsien Ng, Vivek Subbiah, Wells A. Messersmith, Vincenzo Teneggi, (unknown), Kantharaj Ethirajulu, Pauline Yeo, (unknown), (unknown), Stéphanie Blanchard, Ranjani Nellore, (unknown), (unknown), (unknown), Jeffrey Hill, Babita Madan, David M. Virshup, A. Matter	12
6	152O A phase 1, first-in-human dose escalation study of ETC-159 in advanced or metastatic solid tumours 2016 ·Annals of Oncology ·Vincenzo Teneggi, Matthew Ng, David S.P. Tan, Vivek Subbiah, Colin D. Weekes, (unknown), Kantharaj Ethirajulu, Pauline Yeo, (unknown), (unknown), Stéphanie Blanchard, Ranjani Nellore, (unknown), Jeffrey Hill, David M. Virshup, Babita Madan, A. Matter	10
7	Structure and Ligand-Based Design of mTOR and PI3-Kinase Inhibitors Leading to the Clinical Candidates VS-5584 (SB2343) and SB2602 2014 ·Journal of Chemical Information and Modeling ·Anders Poulsen, Harish Nagaraj, (unknown), Stéphanie Blanchard, (unknown), (unknown), Haishan Wang, Stefan Hart, Kee Chuan Goh, Brian Dymock, Meredith Williams	27
8	Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3) 2012 ·Journal of Molecular Modeling ·Anders Poulsen, Anthony D. William, Stéphanie Blanchard, Harish Nagaraj, Meredith Williams, Haishan Wang, (unknown), Eric T. Sun, (unknown), (unknown), Kee Chuan Goh, Brian Dymock	29
9	Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3) 2012 ·Journal of Computer-Aided Molecular Design ·Anders Poulsen, Anthony D. William, Stéphanie Blanchard, (unknown), Harish Nagaraj, Haishan Wang, (unknown), (unknown), Kee Chuan Goh, Brian Dymock	31
10	Thieno[3,2-d]pyrimidin-4(3H)-one derivatives as PDK1 inhibitors discovered by fragment-based screening 2012 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Pondy Murugappan Ramanujulu, Anders Poulsen, Meredith Williams, Stéphanie Blanchard, (unknown), Zahid Bonday, (unknown), Kee Chuan Goh, (unknown), Jeanette M. Wood, Brian Dymock	9
11	2-Anilino-4-aryl-8H-purine derivatives as inhibitors of PDK1 2012 ·Bioorganic & Medicinal Chemistry Letters ·Stéphanie Blanchard, (unknown), (unknown), Anders Poulsen, Zahid Bonday, (unknown), Kee Chuan Goh, (unknown), Mohammad Pasha, Haishan Wang, Meredith Williams, Jeanette M. Wood, Kantharaj Ethirajulu, Brian Dymock	10
12	Structure-based design of PDK1 inhibitors 2011 ·Bioorganic & Medicinal Chemistry Letters ·Anders Poulsen, Stéphanie Blanchard, (unknown), (unknown), Meredith Williams, Haishan Wang, Brian Dymock	11
13	Discovery of Kinase Spectrum Selective Macrocycle (16E)-14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a Potent Inhibitor of Cyclin Dependent Kinases (CDKs), Janus Kinase 2 (JAK2), and Fms-like Tyrosine Kinase-3 (FLT3) for the Treatment of Cancer 2011 ·Journal of Medicinal Chemistry ·Anthony D. William, (unknown), Kee Chuan Goh, Stéphanie Blanchard, Anders Poulsen, (unknown), Harish Nagaraj, (unknown), Haishan Wang, Meredith Williams, Eric T. Sun, Changyong Hu, Ramesh Jayaraman, Mohammad Pasha, Kantharaj Ethirajulu, Jeanette M. Wood, Brian Dymock	78
14	Synthesis and evaluation of alkenyl indazoles as selective Aurora kinase inhibitors 2010 ·Bioorganic & Medicinal Chemistry Letters ·Stéphanie Blanchard, Anthony D. William, (unknown), Anders Poulsen, (unknown), Weiping Deng, Noah P. Tu, (unknown), (unknown), (unknown), (unknown), Kee Chuan Goh, Zahid Bonday, Eric T. Sun	15
15	Structure-based design of Aurora A & B inhibitors 2008 ·Journal of Computer-Aided Molecular Design ·Anders Poulsen, Anthony D. William, (unknown), Stéphanie Blanchard, (unknown), Weiping Deng, Noah P. Tu, (unknown), Eric T. Sun, (unknown), (unknown), (unknown), Kee Chuan Goh, Zahid Bonday	8
16	New Access to Oxazolopyridines via Hydroxyamidine Derivatives: Application to Quinolines. 2004 ·ChemInform ·(unknown), Stéphanie Blanchard, (unknown), Christian Jarry, Jean‐Michel Léger, P. Caubère, Gérald Guillaumet	1
17	Synthesis of Mono- and Bisdihydrodipyridopyrazines and Assessment of Their DNA Binding and Cytotoxic Properties 2004 ·Journal of Medicinal Chemistry ·Stéphanie Blanchard, (unknown), Christelle Tardy, Brigitte Baldeyrou, Christian Bailly, Pierre Colson, Claude Houssier, Stéphane Léonce, Laurence Kraus‐Berthier, Bruno Pfeiffer, Pierre Renard, Alain St. Pierre, P. Caubère, Gérald Guillaumet	7
18	New Access to Oxazolopyridines via Hydroxyamidine Derivatives; Application to Quinolines 2003 ·Synthesis ·P. Caubère, Gérald Guillaumet, (unknown), Stéphanie Blanchard, (unknown), Christian Jarry, Jean‐Michel Léger	3
19	Hetarynic synthesis and chemical transformation of dihydrodipyridopyrazines 2002 ·Tetrahedron ·Stéphanie Blanchard, (unknown), (unknown), Pierre Renard, Bruno Pfeiffer, Gérald Guillaumet, P. Caubère	14
20	Metalation and Functionalization of Dihydrodipyridopyrazines. 2002 ·ChemInform ·Stéphanie Blanchard, (unknown), P. Caubère, Gérald Guillaumet	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact